A Study of Azithromycin in HIV-Infected Patients
Completed · Phase 1
Conditions studied: Bacterial Infections, HIV Infections
In brief
To assess the dose proportionality of azithromycin concentrations and toleration when delivered in tablet formulation to HIV-infected patients. The need exists to further assess the antibacterial agent azithromycin at differing doses in an HIV-infected population.
Key facts
- Study ID
- NCT00002344
- Run by
- Pfizer
- People needed
- 12
- Last updated by the study team
- 2005-06-24
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients must have:
- HIV seropositivity.
- CD4 count <= 500 cells/mm3.
- NO active AIDS opportunistic infection.
You may not qualify if…
- Co-existing Condition:
- Patients with the following symptoms or conditions are excluded:
- Other active intercurrent illness.
- Any condition possibly affecting drug absorption (e.g., ulcers, gastrectomy, HIV-associated enteropathies.
- Signs or symptoms of severe illness that would preclude study participation.
- Known allergies to macrolide antibiotics.
- Patients with the following prior condition are excluded:
- Clinically important change in baseline status within 4 weeks prior to study entry.
- Prior Medication:
- Excluded:
- Investigational drugs including treatment IND drugs within 4 weeks prior to study entry.
- Known drug or alcohol dependence.
Where it is running
- Harris Laboratories Inc — Phoenix, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.